A Multicenter, Open-label, Noncomparative, Japanese Phase III Study to Assess the Efficacy and Safety of Ceftolozane/Tazobactam (MK-7625A) Used in Combination With Metronidazole in Japanese Patients With Complicated Intra-abdominal Infection.

Trial Profile

A Multicenter, Open-label, Noncomparative, Japanese Phase III Study to Assess the Efficacy and Safety of Ceftolozane/Tazobactam (MK-7625A) Used in Combination With Metronidazole in Japanese Patients With Complicated Intra-abdominal Infection.

Completed
Phase of Trial: Phase III

Latest Information Update: 04 Aug 2017

At a glance

  • Drugs Ceftolozane/tazobactam (Primary) ; Metronidazole
  • Indications Intra-abdominal infections
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 01 Aug 2017 Status changed from active, no longer recruiting to completed.
    • 22 Jun 2017 Planned End Date changed from 23 Aug 2017 to 3 Aug 2017.
    • 22 Jun 2017 Planned primary completion date changed from 23 Aug 2017 to 3 Aug 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top